Clinical information for the 20 patients with acute lymphoblastic leukemia and 13 controls included in the study.

BCP indicates B-cell precursor ALL; T-ALL, T-cell ALL; HeH, high hyperdiploidy; amp(21), amplification of chr 21; HR, high risk; SR, standard risk; IR, intermediate risk; NA, not available.aWhite blood cell count at diagnosis (109/L).bThe NOPHO ALL 2000 protocol was used.cDNA from was available from bone marrow taken from the patients on day 29,50, and/or 106 after the initiation of therapy, all patients were in morphological remission with less than 5% leukemic blasts.